Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCardiff Oncology, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 3 | -$0.29 | -$0.20 | -$0.24 |
| Q2 2025 | 2 | -$0.44 | -$0.04 | -$0.24 |
| Q3 2025 | 2 | -$0.45 | -$0.04 | -$0.25 |
| Q4 2025 | 2 | -$0.46 | -$0.04 | -$0.25 |
| Q1 2026 | 1 | -$0.56 | -$0.05 | -$0.31 |
| Q2 2026 | 1 | -$0.58 | -$0.05 | -$0.31 |
| Q3 2026 | 1 | -$0.63 | -$0.06 | -$0.34 |
| Q4 2026 | 1 | -$0.64 | -$0.06 | -$0.35 |
| Q1 2027 | 1 | -$0.74 | -$0.07 | -$0.41 |
| Q2 2027 | 1 | -$0.74 | -$0.07 | -$0.40 |
| Q3 2027 | 1 | -$0.76 | -$0.07 | -$0.42 |
| Q4 2027 | 1 | -$0.76 | -$0.07 | -$0.41 |
Cardiff Oncology, Inc. Earnings Date And Information
Cardiff Oncology, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.25 earnings per share for the quarter, topping analysts' consensus estimates of $-0.27 by $0.02. The company had revenue of 165,000 for the quarter and had revenue of 488,000 for the year. Cardiff Oncology, Inc. has generated $-1 earnings per share over the last year ($-0.93 diluted earnings per share) and currently has a price-to-earnings ratio of -4.64. Cardiff Oncology, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Cardiff Oncology, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.27 | -$0.25 | 0.02 | $70,000 | $165,000 |
| 08/08/2024 | Q2 2024 | -$0.25 | -$0.26 | -0.01 | $58,750 | $163,000 |
| 05/02/2024 | Q1 2024 | -$0.25 | -$0.22 | 0.03 | $205,000 | |
| 02/29/2024 | Q4 2023 | -$0.26 | -$0.21 | 0.05 | $156,000 | |
| 11/02/2023 | Q3 2023 | -$0.29 | -$0.22 | 0.07 | $50,000 | $141,000 |
| 08/09/2023 | Q2 2023 | -$0.27 | -$0.25 | 0.02 | $50,000 | $108,000 |
| 05/04/2023 | Q1 2023 | -$0.23 | -$0.23 | 0 | $83,000 | |
| 03/02/2023 | Q4 2022 | -$0.25 | -$0.18 | 0.07 | $128,000 | |
| 11/03/2022 | Q3 2022 | -$0.27 | -$0.19 | 0.08 | $68,200 | $93,000 |
| 08/04/2022 | Q2 2022 | -$0.25 | -$0.24 | 0.01 | $93,000 | $91,000 |
| 05/05/2022 | Q1 2022 | -$0.23 | -$0.25 | -0.02 | $74,000 | |
| 02/24/2022 | Q4 2021 | -$0.17 | -$0.23 | -0.06 | $133,000 | |
| 11/04/2021 | Q3 2021 | -$0.17 | -$0.17 | 0 | $40,000 | $86,000 |
| 08/05/2021 | Q2 2021 | -$0.15 | -$0.17 | -0.02 | $152,500 | $68,000 |
| 05/06/2021 | Q1 2021 | -$0.14 | -$0.14 | 0 | $72,000 | |
| 02/25/2021 | Q4 2020 | -$0.15 | -$0.28 | -0.13 | $119,255 | |
| 11/05/2020 | Q3 2020 | -$0.20 | -$0.19 | 0.01 | $50,000 | $136,401 |
| 08/11/2020 | Q2 2020 | -$0.24 | -$0.28 | -0.04 | $29,676 | $42,633 |
| 05/07/2020 | Q1 2020 | -$0.41 | $67,704 | |||
| 02/27/2020 | Q4 2019 | -$0.57 | -$0.51 | 0.06 | $93,000 |
Cardiff Oncology, Inc. Earnings: FAQ's
When is Cardiff Oncology, Inc.'s earnings date?
Cardiff Oncology, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
Did Cardiff Oncology, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Cardiff Oncology, Inc. (:CRDF) reported $-0.25 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.27 by $0.02.
How can I listen to Cardiff Oncology, Inc.'s earnings conference
call?
The conference call for Cardiff Oncology, Inc.'s latest earnings report can be listened to online.
How can I read Cardiff Oncology, Inc.'s conference call transcript?
The conference call transcript for Cardiff Oncology, Inc.'s latest earnings report can be read online.
How much revenue does Cardiff Oncology, Inc. generate each year?
Cardiff Oncology, Inc. (:CRDF) has a recorded annual revenue of $488,000.
How much profit does Cardiff Oncology, Inc. generate each year?
Cardiff Oncology, Inc. (:CRDF) has a recorded net income of $488,000. Cardiff Oncology, Inc. has generated $-0.93 earnings per share over the last four quarters.
What is Cardiff Oncology, Inc.'s price-to-earnings ratio?
Cardiff Oncology, Inc. (:CRDF) has a price-to-earnings ratio of -4.64 and price/earnings-to-growth ratio is 1.41.